Valuation: StemRIM

Market Cap 1.87TCr 12Cr 10Cr 9.42Cr 8.62Cr 16Cr 1.12TCr 16Cr 111.26Cr 43Cr 564.73Cr 44Cr 43Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.17TCr 7.35Cr 6.3Cr 5.89Cr 5.39Cr 10Cr 703.26Cr 10Cr 70Cr 27Cr 353.28Cr 28Cr 27Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
49.63%
Yield 2024 *
-
Yield 2025 -
1 day+0.56%
1 week+2.59%
Current month+19.80%
1 month+21.43%
3 months+21.84%
6 months+19.40%
Current year+35.74%
1 week 337
Extreme 337
368
1 month 280
Extreme 280
368
Current year 260
Extreme 260
368
1 year 246
Extreme 246
368
3 years 246
Extreme 246
881
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%+2.59%+13.33%-58.97% 14Cr
+0.90%+3.80%+41.49%-0.78% 8.33TCr
+8.86%+129.20%+435.14%+24.85% 5.79TCr
-1.69%+23.30%-22.30%-36.29% 5.78TCr
-1.46%+0.19%-2.06%+30.50% 5.17TCr
+1.74%+4.43%+12.37%+169.64% 4.93TCr
+1.13%+3.31%+55.61%-17.57% 3.2TCr
+0.46%+6.37%+50.29%+97.27% 2.59TCr
+1.19%+9.17%+2.97%+230.86% 2.27TCr
-0.30%+4.45%+58.29%+118.84% 1.69TCr
Average +1.14%+18.68%+64.51%+55.84% 3.98TCr
Weighted average by Cap. +1.44%+24.97%+80.50%+46.33%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.27Cr -1.09Cr -1.02Cr -93.32L -1.75Cr -121.69Cr -1.77Cr -12Cr -4.7Cr -61Cr -4.78Cr -4.67Cr -192.9Cr -1.21Cr -1.04Cr -97.25L -89.02L -1.67Cr -116.1Cr -1.69Cr -11Cr -4.48Cr -58Cr -4.56Cr -4.46Cr
Net Debt -841Cr -5.29Cr -4.53Cr -4.24Cr -3.88Cr -7.28Cr -506.15Cr -7.38Cr -50Cr -20Cr -254.26Cr -20Cr -19Cr -699.4Cr -4.4Cr -3.77Cr -3.53Cr -3.23Cr -6.06Cr -420.93Cr -6.14Cr -42Cr -16Cr -211.45Cr -17Cr -16Cr
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
21/26/21 JP¥357.00 +0.56% 4,95,100
20/26/20 JP¥355.00 +3.50% 3,83,200
19/26/19 JP¥343.00 -1.44% 4,92,700
18/26/18 JP¥348.00 0.00% 5,46,600
17/26/17 JP¥348.00 0.00% 3,97,200
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock